GSK announces results of late-stage clinical trial for albiglutide

LONDON — GlaxoSmithKline announced the results from the first of eight phase-3 clinical trials that examined the efficacy of albiglutide in the treatment of Type 2 diabetes.

The Harmony 7 trial was a 32-week, head-to-head, open-label, noninferiority study that compared albiglutide, an investigational once weekly glucagon-like peptide-1 agonist, with once-daily liraglutide. According to the results, patients administered GSK's drug saw a 0.78% reduction in HbA1C, while patients administered liraglutide saw a 0.99% reduction in HbA1C.

“While the prespecified margin of noninferiority was not met, these topline data support continued progression towards registration of albiglutide as a possible future once weekly treatment for Type 2 diabetes,” GSK chairman of research and development Moncef Slaoui said. “This is the first of eight phase-3 studies to conclude and we continue to look forward to receiving the results of the remaining studies which will provide a more complete assessment of the profile of albiglutide in Type 2 diabetes,” he added.

GSK said that initial results from the remaining seven phase-3 studies will become available over the course of the next several months.

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.